pGy2 program
Residency Program Director
-
Tracy Wiczer, PharmD, BCOP
- PGY2 Oncology Residency Program Director, The James Cancer Hospital at The Ohio State University
- PGY2 Oncology, The James Cancer Hospital at The Ohio State University
- PGY1, The Jewish Hospital-Mercy Health, Cincinnati, Ohio
- PharmD, University of Cinicinnati
Previous Year Residents
-
Jasmine Browning, PharmD
Hematology/Oncology Clinical Pharmacist, University of Louisville Hospital Brown Cancer Center -
Tyler Smith, PharmD
Hematology/Oncology Pharmacist Specialist at The James Cancer Hospital -
Anna Clennon, PharmD
Clinical Pharmacy Oncology/Hematology Specialist at Froedtert Hospital and the Medical College of Wisconsin -
Riley Karpen, PharmD, MBA
Clinical Oncology Pharmacist - The University of Kansas Health System -
TJ Schieber, PharmD, MBA
Clinical Oncology Pharmacist - The University of Kansas Health System -
Megan Fleming, PharmD
Hematology/Oncology Pharmacist Specialist, The James Cancer Hospital -
Lexus Frazier, PharmD
Hematology/Oncology Pharmacist Specialist at The James Cancer Hospital -
Samantha Musson, PharmD
Hematology/Oncology Pharmacist Specialist at Christ Hospital in Cincinnati, Ohio -
Shivani Prakshesh Patel, PharmD
Clinical Pharmacist Specialist, University of Chicago Medicine -
LeeAnn Geraghty, PharmD
Clinical Hematology/Oncology Specialist Pharmacist, Norton Healthcare, Louisville, KY
About the PGY2 Oncology Residency Program
Residency Sites
The Ohio State University Comprehensive Cancer Center – James Cancer Hospital is ranked nationally as one of the top hospitals for cancer care, maintaining an “exceptional” rating – the highest descriptor given by the National Cancer In
stitute, and is the third largest cancer center in the nation. Opened in December 2014, with 21 floors spanning 1.1 million square feet, the new James Cancer Hospital and Solove Research Institute revolutionizes the way cancer prevention and care are provided, with over 200 specialized oncologists and cancer researchers working side-by-side to unlock the mysteries of what causes cancer and, using those discoveries, transition from cancer treatment to cancer prevention.
Read More
This 356-bed adult cancer clinical care facility, including a 36-bed blood and marrow transplant unit, is a member of the National Comprehensive Cancer Network, the National Cancer Institute’s National Clinical Trial Network— notably one of only four centers funded by the NCI to conduct both Phase I and II clinical trials on novel anticancer drugs, achieved Magnet® designation for excellence in patient care, and is fully accredited by the Joint Commission, the American College of Surge
ons Common on Cancer and the Foundation for the Accreditation of Cellular Therapy. The center includes six outpatient chemotherapy infusion clinics, dispensing an estimate of over 75,000 doses of chemotherapy annually. The Department of Pharmacy consists of inpatient and outpatient hematology/oncology clinical specialist pharmacists, pain and palliative medicine pharmacists, anti-coagulation pharmacists, cancer informatics pharmacists, medication assistance pharmacists, and Hematology/Oncology specialty practice pharmacy residents.
The James Cancer Hospital at The Ohio State University offers a one-year postgraduate year two (PGY2) ASHP accredited oncology pharmacy residency program. The clinical pharmacy program is designed to align with our subspecialized disease specific model allowing residents the opportunity to train with clinical specialists who are experts in their subspecialty in both inpatient and ambulatory clinic setting. The program allows residents to develop their hematology/oncology knowledge base including cancer treatment, supportive care, and the role of clinical trials in this patient population. Upon completion of the program, the resident will have the skillset necessary to work as a respected member of a multi-disciplinary hematology/oncology patient care team.
KEY ROTATIONS/EXPERIENCES
The resident will complete a combination of rotations and longitudinal experiences designed around the core objectives specified by ASHP in addition to the resident’s interest.
Orientation: 4 weeks (orientation may be modified for early commit residents)
Research: 3-4 weeks
Hematology
- Inpatient Acute Leukemia – 4 weeks
- Bone Marrow Transplantation – 4 weeks
- Inpatient Lymphoma – 4 weeks
- Outpatient Hematology Clinics (Chronic Leukemias, Multiple Myeloma, & lymphoma)
Oncology
- Inpatient Oncology – 4 weeks
- Outpatient Solid Tumor Clinics
- Outpatient Breast Cancer – 3 weeks
- Outpatient Gastrointestinal Cancers (GI) + Melanoma – 4 weeks
- Outpatient Lung (thoracic)/Gynecology Oncology (Gyn Onc) – 3 weeks
- Outpatient Genitourinary (GU) – 3 weeks
Clinical trials unit (CTU): 1 week
Pain and Palliative: 2 weeks
Administration: 1 week
- Required Longitudinal
- Medication Assistance
- Medication Safety
- Teaching
- Research/MUE
Electives: 4-8 weeks, experiences can be 1-4 weeks in length, electives not listed below can be arranged on specific request
- Anything in required repeated
- Inpatient leukemia/transplant
- Inpatient CLL/MM/misc heme
- Inpatient benign heme
- Outpatient Leukemia/BMT
- Outpatient Head & Neck/Sarcoma
- Outpatient Melanoma
- Outpatient Gynecology Oncology
- Outpatient Neuro-oncology
- Oncology Administration
- Informatics
- Infectious Diseases
- Pediatric Hematology/Oncology (Nationwide Children’s Hospital)
Key Preceptors
Learn more about the Hematology/Oncology key preceptors:
Read MoreINPATIENT/OUTPATIENT HEMATOLOGY
- Rebecca Evers, PharmD, BCOP
Outpatient Multiple Myeloma and Lymphoma - Solmaz Karimi, PharmD
Inpatient/Outpatient Benign Hematology, Chronic Lymphocytic Leukemia, & Lymphoma - Pooja Kumar, PharmD, BCOP
Inpatient/Outpatient BMT and Acute Leukemia - Tracelyn Freeman, PharmD, BCOP
Inpatient/Outpatient BMT and Acute Leukemia - Megan Fleming, PharmD
Inpatient/Outpatient BMT and Acute Leukemia - Jeremy Sen, PharmD, BCOP
Inpatient/Outpatient BMT and Acute Leukemia - Justin Tossey, PharmD, BCOP
Inpatient/Outpatient BMT and Acute Leukemia - Ally Waller, PharmD, BCOP
Inpatient/Outpatient BMT and Acute Leukemia - Caitlyn Crawford, PharmD, BCOP
Inpatient/Outpatient Benign Hematology, Chronic Lymphocytic Leukemia, and Lymphoma - Lindsay Rosen, PharmD, BCOP
Inpatient/Outpatient Benign Hematology, Chronic Lymphocytic Leukemia, and Lymphoma - Jordan Lundberg, PharmD, BCOP
Inpatient/Outpatient Benign Hematology, Chronic Lymphocytic Leukemia, and Lymphoma - Tracy Wiczer, PharmD, BCOP
Inpatient/Outpatient Benign Hematology, Chronic Lymphocytic Leukemia, and Lymphoma
INPATIENT/OUTPATIENT ONCOLOGY
- Matt Arango, PharmD, BCOP
Outpatient Gastrointestinal Cancer - Tyler Everhardt, PharmD
Inpatient Medical Oncology/Outpatient Melanoma & Neuroendocrine - Lexus Frazier, PharmD
Inpatient/Outpatient BMT and Acute Leukemia - Caleb Good, PharmD
Inpatient Medical Oncology/Outpatient Melanoma & Neuroendocrine - Dat Le, PharmD, BCOP
Outpatient Gastrointestinal Cancer/Neuroendocrine - Brianna Archambeau, PharmD, BCOP
Inpatient Medical Oncology - Hunter Patton, PharmD, BCPS
Inpatient Medical Oncology - Molly Russell, PharmD
Inpatient Medical Oncology/Outpatient Head & Neck Cancer - Andrew Stone, PharmD, BCPS
Inpatient Medical Oncology - Michael Berger, PharmD, BCOP
Outpatient Breast Cancer - Stephanie Collins, PharmD, BCOP
Outpatient Breast Cancer - Eric Fela, PharmD, BCOP
Outpatient Gynecologic Cancers - Ambar Khan, PharmD, BCOP
Outpatient Gynecologic Cancers - Megan Hinkley, PharmD, BCOP
Outpatient Genitourinary Cancers, Lung Cancer - Sarah Hoffman, PharmD, BCOP
Outpatient Sarcoma - Gretchen Pardo, PharmD, BCOP
Inpatient Medical Oncology/Outpatient Head & Neck Cancer - Hiba Alzouby, PharmD
Outpatient Gastrointestinal Oncology - Kristen Nymberg, PharmD, BCOP
Outpatient Genitourinary - Lauren Ledbetter, PharmD, BCOP
Outpatient Lung Cancer - Michael Smith, PharmD, BCOP
Outpatient Breast Cancer - Jaelyn Westfield, PharmD, BCOP
Outpatient Multiple Myeloma and Lymphoma
HEMATOLOGY/ONCOLOGY FLOATS
- Connor Aossey, PharmD
Hematology/Oncology Float - Tyler Dickerson, PharmD, BCOP
Hematology/Oncology Float - Taylor Gabbard, PharmD
Hematology/Oncology Float - Natalia Hartzler, PharmD, BCOP
Hematology/Oncology Float - Tommy Montgomery, PharmD, BCOP
Hematology/Oncology Float - Allison Reed, PharmD, BCOP
Hematology/Oncology Float - Tyler Smith, PharmD
Hematology/Oncology Float
HEMATOLOGY/ONCOLOGY ANTICOAGULATION
- Paige Erdeljac, PharmD, BCACP
Hematology/Oncology Anticoagulation - Stephanie Yager, PharmD, BCACP
Hematology/Oncology Anticoagulation
PAIN AND PALLIATIVE MEDICINE
- Jessica Hirsch, PharmD
Palliative Medicine - Gary Houchard, PharmD
Palliative Medicine - Justin Kullgren, PharmD, CPE
Palliative Medicine - Kyle Quirk, PharmD
Palliative Medicine - Maureen Saphire, PharmD, BCGP, CDP
Palliative Medicine
OTHER HEMATOLOGY AND ONCOLOGY PRECEPTORS
- Amber Hartman, PharmD
Medication Safety - Naomi Digiantonio, PharmD, BCPS
Generalist Pharmacist, Clinical Trials Unit - Justin Osorio, PharmD, BCPS
Generalist Pharmacist, Inpatient Benign Hematology - Jacquelyn Williams, PharmD
Generalist Pharmacist, Inpatient Benign Hematology
ADMINISTRATION
- Hallie Barr, PharmD, BCOP
Pharmacy Manager, Investigational Drug Services - Janinah Barreto, PharmD, MS, CPHIMS
Assistant Director, Pharmacy Informatics Clinical Applications - Mitch Dorn, PharmD, MS
Associate Director, Central Pharmacies - Morgan Forshay, PharmD, MS, BCPS
Pharmacy Manager, Inpatient Oncology - Sarah Hudson-Disalle, PharmD
Pharmacy Manager, Prior Authorization - Julie Kennerly-Shah, PharmD, MS, MHA, BCPS
Associate Director, Cancer Pharmacy Services - Ben Lopez, PharmD, MS, MHA, BCPS
Director, Enterprise Operations - Stephen Polley, PharmD, MPA, MS, BCPS
Assistant Director, Cancer Pharmacy Services - Heather Armbruster, PharmD, BCOP
Pharmacy Manager, Clinical Outpatient Services - Emily Dotson, PharmD, BCOP
Pharmacy Manager, Clinical Inpatient Services
Selected RESIDENT RESEARCH
- Real world use of enfortumab vedotin for metastatic urothelial carcinoma A. Clennon
- First-line immunotherapy for metastatic NSCLC following progression on or after durvalumab for unresectable stage III NSCLC following chemoradiation, J. Browning
- Evaluation of the efficacy of fosaprepitant, olanzapine, and palonosetron for the prevention of nausea and vomiting in patients receiving melphalan-based allogeneic transplant R. Karpen
- Effect of Proton Pump Inhibitors on Patients Receiving Palbociclib Tablets as First-Line Treatment for Hormone Receptor Positive HER2-Negative Metastatic Breast Cancer TJ Schieber
- Efficacy and tolerability of cetuximab vs cetuximab/carboplatin/paclitaxel for metastatic cutaneous squamous cell carcinoma T. Smith
Benefits and Additional Requirements
Application Deadline: January 2
We welcome applications from non-U.S. citizens who have a “green card” (permanent resident status) or a current visa valid through the entire duration of the residency program. The Ohio State University pharmacy residency programs are NOT able to sponsor visas for pharmacy residents (PGY1 or PGY2).
Start Date: July 1
Annual Salary – $50,500
Vacation Days – 10 Days
Staffing Requirement – 20 weekends per year
Completion of a Major Research Project
You must be logged in to post a comment.